| train (N=92) |
validation (N=102) |
P-value | |
|---|---|---|---|
| Age(years) | |||
| Mean (SD) | 63.3 (7.91) | 64.1 (8.33) | 0.737 |
| Median [Min, Max] | 64.5 [35.0, 76.0] | 66.0 [33.0, 80.0] | |
| Sex | |||
| FeMale | 10 (10.9%) | 11 (10.8%) | 1 |
| Male | 82 (89.1%) | 91 (89.2%) | |
| Smoking | |||
| No | 16 (17.4%) | 32 (31.4%) | 0.0369 |
| Yes | 76 (82.6%) | 70 (68.6%) | |
| Pathologic subtype | |||
| Non squamous | 48 (52.2%) | 58 (56.9%) | 0.61 |
| Squamous | 44 (47.8%) | 44 (43.1%) | |
| PFS(months) | |||
| Mean (SD) | 15.3 (10.6) | 13.4 (6.44) | 0.291 |
| Median [Min, Max] | 12.5 [0.600, 37.4] | 13.1 [0.367, 27.9] | |
| OS(months) | |||
| Mean (SD) | 20.7 (10.7) | 14.5 (6.47) | 0.285 |
| Median [Min, Max] | 20.9 [1.33, 39.3] | 14.8 [0.367, 27.9] | |
| PD-L1 TPS group | |||
| <1% | 11 (12.0%) | 9 (8.8%) | 0.596 |
| 1-50% | 19 (20.7%) | 16 (15.7%) | |
| >=50% | 12 (13.0%) | 18 (17.6%) | |
| Missing | 50 (54.3%) | 59 (57.8%) | |
| Clinical benefit | |||
| DCB | 69 (75.0%) | 89 (87.3%) | 0.039 |
| NDB | 23 (25.0%) | 12 (11.8%) | |
| Unknown | 0 (0%) | 1 (1.0%) | |
| LDH | |||
| Mean (SD) | 241 (160) | 242 (189) | 0.702 |
| Median [Min, Max] | 189 [66.7, 1110] | 193 [96.0, 1660] | |
| Missing | 1 (1.1%) | 5 (4.9%) | |
| NLR | |||
| Mean (SD) | 3.84 (2.05) | 4.05 (2.74) | 0.38 |
| Median [Min, Max] | 3.37 [1.04, 9.80] | 3.30 [1.15, 16.3] | |
| Missing | 0 (0%) | 2 (2.0%) | |
| Bone metastasis | |||
| No | 59 (64.1%) | 51 (50.0%) | 0.066 |
| Yes | 33 (35.9%) | 51 (50.0%) | |
| Brain metastasis | |||
| No | 76 (82.6%) | 86 (84.3%) | 0.9 |
| Yes | 16 (17.4%) | 16 (15.7%) | |
| Liver metastasis | |||
| No | 84 (91.3%) | 83 (81.4%) | 0.0738 |
| Yes | 8 (8.7%) | 19 (18.6%) | |
| Pleura metastasis | |||
| No | 69 (75.0%) | 71 (69.6%) | 0.499 |
| Yes | 23 (25.0%) | 31 (30.4%) | |
| Lymph metastasis | |||
| No | 46 (50.0%) | 36 (35.3%) | 0.0542 |
| Yes | 46 (50.0%) | 66 (64.7%) |